

## Special Issue

# Vaccines for Tuberculosis Control

### Message from the Guest Editors

Tuberculosis (TB), caused by *Mycobacterium tuberculosis*, remains a major cause of death worldwide. Despite the century-old BCG vaccine, TB continues to threaten health, particularly in low- and middle-income countries. Drug-resistant strains complicate control, underscoring the need for broad protection. Recent advancements have transformed Mtb vaccine research. Integrating multi-omics with bioinformatics enables effective vaccine design. Candidates must contain novel immunodominant epitopes for immune cells. Predicting antigen-MHC binding and mapping protective pathways are essential, while machine learning accelerates next-generation mRNA and viral vector vaccines. This Special Issue presents scientific findings in TB vaccine development. It features research and reviews enhancing understanding of immune mechanisms, antigen discovery, and vaccine translation. We welcome original research, reviews, and perspectives. Research areas include:

- Novel vaccine candidates;
- Recombinant and live-attenuated vaccine;
- Host-vaccine interaction;
- New animal models for evaluation;
- Subunit, peptide, viral, and mRNA-based TB vaccines;
- Adjuvant immunology and delivery strategies.

---

### Guest Editors

Prof. Dr. Subramanian Dhandayuthapani

Department of Medicine and Oncology, University of Texas Rio Grande Valley, Edinburg, TX, USA

Prof. Dr. Chinnaswamy Jagannath

Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston, TX 77030, USA

---

### Deadline for manuscript submissions

15 June 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/258458](https://mdpi.com/si/258458)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).